Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$4.52 +3.9%	$4.12	$1.58 ▼ $7.27	$402.66M	-0.6	1.22 million shs	446,268 shs
COYA Coya Therapeutics	$5.87 +3.2%	$6.06	$4.65 ▼ $10.24	$98.18M	0.49	73,305 shs	37,431 shs
PRTA Prothena	$6.72 -2.5%	$10.47	$6.47 ▼ $25.42	$361.72M	0.11	583,178 shs	1.12 million shs
PRTC PureTech Health	$16.43 -1.7%	$17.20	$13.30 ▼ $32.98	$394.63M	1.14	4,618 shs	578 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-3.12%	-10.40%	+11.54%	+21.17%	+132.62%
COYA Coya Therapeutics	-1.22%	-5.87%	+4.40%	-16.81%	-31.03%
PRTA Prothena	-9.22%	-5.49%	-30.68%	-50.40%	-66.68%
PRTC PureTech Health	-3.21%	-4.67%	-1.35%	-11.17%	-40.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.3821 of 5 stars	3.6	2.0	2.7	4.2	1.3
COYA Coya Therapeutics	2.3749 of 5 stars	3.5	5.0	2.0	0.8	0.0
PRTA Prothena	3.6621 of 5 stars	4.4	3.0	2.8	1.7	1.3
PRTC PureTech Health	2.4561 of 5 stars	3.8	4.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.13	Buy	$9.83	117.55% Upside
COYA Coya Therapeutics	3.00	Buy	$17.00	189.61% Upside
PRTA Prothena	2.88	Moderate Buy	$51.71	669.56% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	173.89% Upside

Current Analyst Ratings Breakdown

Latest COYA, AMLX, PRTA, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/13/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/9/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$48.00 ➝ $30.00
5/9/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$80.00 ➝ $78.00
5/9/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-316.56	$0.82 per share	5.51	$6.42 per share	0.70
COYA Coya Therapeutics	$3.55M	27.62	N/A	N/A	$2.47 per share	2.38
PRTA Prothena	$137.94M	2.62	N/A	N/A	$10.46 per share	0.64
PRTC PureTech Health	$4.32M	91.46	N/A	N/A	$16.94 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	N/A
COYA Coya Therapeutics	-$7.99M	-$0.98	N/A	N/A	N/A	N/A	-31.63%	-27.76%	N/A
PRTA Prothena	-$147.03M	-$2.08	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	N/A
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest COYA, AMLX, PRTA, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million
2/20/2025	Q4 2024	PRTA Prothena	-$1.02	-$1.08	-$0.06	-$1.08	$7.53 million	$2.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	22.48%	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
COYA Coya Therapeutics	N/A	15.31	15.31
PRTA Prothena	N/A	11.52	11.52
PRTC PureTech Health	N/A	3.68	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
COYA Coya Therapeutics	39.75%
PRTA Prothena	97.08%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
COYA Coya Therapeutics	12.00%
PRTA Prothena	9.20%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.08 million	60.53 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable

COYA, AMLX, PRTA, and PRTC Headlines

Recent News About These Companies

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025 | businesswire.com

Leerink Partnrs Predicts PureTech Health FY2025 Earnings

May 6, 2025 | marketbeat.com

FY2025 EPS Estimates for PureTech Health Raised by Analyst

May 5, 2025 | americanbankingnews.com

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025 | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1, 2025 | pharmiweb.com

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30, 2025 | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

PureTech Health plc (NASDAQ:PRTC) Short Interest Down 61.5% in March

April 17, 2025 | marketbeat.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

PureTech Health Shares Fall After Nordic Capital Withdraws Offer Plan

April 8, 2025 | marketwatch.com

Nordic Capital steps away from potential PureTech Health buyout

April 7, 2025 | fiercebiotech.com

PureTech Health plc Statement Regarding Press Speculation

April 7, 2025 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

March 11, 2025 | finance.yahoo.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2025 | finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via ...

February 12, 2025 | businesswire.com

Trend Tracker for (PRTC)

February 2, 2025 | news.stocktradersdaily.com

PureTech Health Plc (NASDAQ: PRTC)

January 30, 2025 | fool.com

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, AMLX, PRTA, and PRTC Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.52 +0.17 (+3.91%)

As of 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Coya Therapeutics NASDAQ:COYA

$5.87 +0.18 (+3.16%)

As of 04:00 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Prothena NASDAQ:PRTA

$6.72 -0.17 (-2.47%)

As of 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PureTech Health NASDAQ:PRTC

$16.43 -0.29 (-1.73%)

As of 02:02 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time